Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPDDPIPELINEPressRett Syndrome

Anavex Adds Dr. Paul Aisen to Scientific Advisory Board

February 16, 2011

Anavex Comments on President Obama’s Signing of National Alzheimer’s Project Act into Law

January 18, 2011

Alzheimer’s Weekly Names ANAVEX 2-73 the Number One Most Promising Trial Drug in Alzheimer’s Disease and Anavex’s Phase I Clinical Program as “Trial of the Year”

January 6, 2011

Anavex Files Phase I Regulatory Submission for ANAVEX 2-73 in Alzheimer’s Disease

December 21, 2010

Anavex Appoints David Tousley as CFO

September 30, 2010

ANAVEX 2-73: Journal of Psychopharmacology Publishes Anti-Amnesic and Neuroprotective Data Against Amyloid Toxicity For First of a New Class in Alzheimer’s Disease

September 13, 2010

Neuroprotective efficacy of ANAVEX 2-73, a novel tetrahydrofuran derivative targeting the sigma-1 chaperone protein, in a mouse model of Alzheimer’s disease: Analyses of administration schedules and combination studies with donepezil and memantine.

September 11, 2010

Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 ligand ANAVEX 2-73, a novel aminotetrahydrofuran derivative.

September 9, 2010

Anavex to Present at Rodman & Renshaw Healthcare Conference September 13 in New York City

September 8, 2010

Dr. Cameron Durrant Named One of PharmaVOICE’s 100 Most Inspiring People in the Pharmaceutical Industry for 2010

August 30, 2010

Anavex Appoints Contract Research Organizations to Initiate Phase I/IIa Clinical Programs, Regulatory Strategies in Alzheimer’s Disease

August 10, 2010

Anavex Reports Animal Study Results as Lead Alzheimer’s Compound Approaches Phase 1 Clinical Trials

May 4, 2010
1
2345678910111213141516171819202122232425262728
…2930313233…
343536373839404142
43

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top